Published in J Neurovirol on December 19, 2016
HIV induces expression of complement component C3 in astrocytes by NF-κB-dependent activation of interleukin-6 synthesis. J Neuroinflammation (2017) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet (1999) 10.28
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) (2005) 4.96
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol (1993) 3.73
Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS (2005) 2.07
Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol (1996) 1.83
CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology (2005) 1.73
Early penetration of the blood-brain-barrier by HIV. Neurology (1988) 1.62
HIV-associated neurocognitive disorder. Lancet Infect Dis (2013) 1.60
The role of viral introductions in sustaining community-based HIV epidemics in rural Uganda: evidence from spatial clustering, phylogenetics, and egocentric transmission models. PLoS Med (2014) 1.43
Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol (1999) 1.42
Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease. J Neuropathol Exp Neurol (1994) 1.36
The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol (2008) 1.31
Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol (2005) 1.30
Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int (2001) 1.29
S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J Neurochem (1998) 1.22
Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol (2004) 1.21
Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol Dis (2000) 1.14
S100B protein in neurodegenerative disorders. Clin Chem Lab Med (2011) 1.14
Human immunodeficiency virus type 1 alters brain-derived neurotrophic factor processing in neurons. J Neurosci (2012) 1.11
Neuronal number and volume alterations in the neocortex of HIV infected individuals. J Neurol Neurosurg Psychiatry (1993) 1.09
Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res Ther (2014) 1.08
Cerebrospinal fluid S-100beta and its relationship with AIDS dementia complex. J Clin Virol (2001) 0.88
Interleukin-6 and granulocyte macrophage-CSF in the cerebrospinal fluid from HIV infected subjects with involvement of the central nervous system. Arq Neuropsiquiatr (1992) 0.85
Yin and Yang of PDGF-mediated signaling pathway in the context of HIV infection and drug abuse. J Neuroimmune Pharmacol (2013) 0.81
A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda. Elife (2016) 0.81
Association of Medical Male Circumcision and Antiretroviral Therapy Scale-up With Community HIV Incidence in Rakai, Uganda. JAMA (2016) 0.75
HIV policy implementation in two health and demographic surveillance sites in Uganda: findings from a national policy review, health facility surveys and key informant interviews. Implement Sci (2017) 0.75
The validity of self-reported antiretroviral use in persons living with HIV: a population-based study. AIDS (2017) 0.75